{"entity":{"id":"nct05798819","kind":"trial","name":"A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervic","aka":[],"tldr":"A phase 3 trial of Zimberelimab run by Guangzhou Gloria Biosciences Co., Ltd. in cervical cancer, now recruiting.","summary":"A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer is a phase 3 interventional study registered as NCT05798819 by Guangzhou Gloria Biosciences Co., Ltd., with 424 participants planned, started 2023-04-20. Conditions listed: Persistent, Recurrent, or Metastatic Cervical Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05798819","url":"https://clinicaltrials.gov/study/NCT05798819"}],"tags":["ctgov-ingest"],"related":[],"cancers":["cervical"],"sections":[],"technologies":[],"targets":[],"drugs":["zimberelimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05798819","phase":"3","setting":"A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate GLS-010 Plus Platinum-containing Chemotherapy With or Without Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer","sponsor":"Guangzhou Gloria Biosciences Co., Ltd.","enrolled":424,"outcomes":[]},"route":"/trials/nct05798819/","neighbours":{"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"}],"drug":[{"id":"zimberelimab","kind":"drug","name":"Zimberelimab","route":"/drugs/zimberelimab/"}]}}